SGO 2022 Conference Coverage on VuMedi

 

Videos
06:44

SGO 2022 Conference Coverage on VuMedi

SGO 2022 Effectiveness & Safety of Neoadjuvant Niraparib in Advanced Ovarian Cancer With HRD: A Prospective, Multicenter Phase 2 Single-Arm Study (NANT)

FEATURING Qinglei Gao
  • 30 views
  • May 13, 2022
10:52

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on Health Care Services Burden in Ovarian Cancer Patients Receiving PARPi Maintenance Treatment

FEATURING Dana Chase
  • 188 views
  • April 7, 2022
  • 1
07:31

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: A Cost-Effectiveness Analysis

FEATURING David Barrington
  • 239 views
  • April 7, 2022
  • 1
05:21

SGO 2022 Conference Coverage on VuMedi

SGO 2022 Phase II Trial of Maintenance Niraparib in Stage III/IV or Platinum-Sensitive Recurrent Uterine Serous Carcinoma

FEATURING Marina Frimer
  • 203 views
  • April 7, 2022
08:08

SGO 2022 Conference Coverage on VuMedi

SGO 2022 Final OS Results From SOLO3: Phase III Trial Assessing Olaparib Monotherapy vs. Non-Platinum Chemo in Heavily Pretreated Patients With Germline BRCA1 and/or BRCA2m Platinum-Sensitive Relapsed Ovarian Cancer

FEATURING Richard Penson
  • 337 views
  • April 7, 2022
  • 1
06:03

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on a Phase 2 OVARIO Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Frontline PBC With Bevacizumab

FEATURING Melissa Hardesty
  • 289 views
  • April 1, 2022
  • 1
13:30

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on a Randomized Phase 3 Trial of IP vs. IV Carboplatin With Dose-Dense Weekly Paclitaxel in Ovarian/Fallopian Tube/Primary Peritoneal Carcinoma

FEATURING Keiichi Fujiwara
  • 273 views
  • April 1, 2022
  • 1
11:28

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on Clinical Outcomes of Ovarian Cancer Patients Treated With the Novel Engineered Cytokine Nemvaleukin Alfa + Pembro: Recent Data From ARTISTRY-1

FEATURING Ira Winer
  • 246 views
  • April 1, 2022
  • 1
11:28

SGO 2022 Conference Coverage on VuMedi

SGO 2022: Recognition and Management of Side Effects Associated With PARPi Therapy for OC

FEATURING Mansoor Raza Mirza
  • 133 views
  • March 29, 2022
  • 1
10:41

SGO 2022 Conference Coverage on VuMedi

SGO 2022: Development of an Interactive Precision Medicine Dashboard to Aid in Completion of Germline and HRD Tumor Testing for ND Ovarian Cancer to Improve the Use of PARPi Frontline Maintenance

FEATURING Ashley Haggerty
  • 58 views
  • March 24, 2022
07:22

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on Shared Decision Making in Frontline Maintenance Therapy for Ovarian Cancer: A Qualitative Assessment

FEATURING Ashley Haggerty
  • 213 views
  • March 24, 2022
  • 1
09:08

SGO 2022 Conference Coverage on VuMedi

SGO 2022 on Maintenance Therapy in Advanced Ovarian Cancer: Results From Key Clinical Trials

FEATURING Dana Chase
  • 279 views
  • March 24, 2022
  • 2
07:24

SGO 2022 Conference Coverage on VuMedi

SGO 2022 Update on Maintenance Olaparib Rechallenge in Patients With Ovarian Carcinoma: Results From the OReO/ENGOT Ov-38 Trial

FEATURING Eric Pujade-Lauraine
  • 74 views
  • March 24, 2022